Pfizer’s Lyrica fails phase 3 trial in epilepsyPfizer’s Lyrica has failed to meet its primary endpoint in a phase 3 trial in primary generalised tonic-clonic Share XPfizer’s Lyrica fails phase 3 trial in epilepsyhttps://pharmaphorum.com/news/pfizers-lyrica-fails-phase-3-trial-in-epilepsy/
Zogenix slumps after FDA refuses epilepsy drug fileZogenix’s only drug candidate is facing a long delay after the FDA refused to accept its marketing application, Share XZogenix slumps after FDA refuses epilepsy drug filehttps://pharmaphorum.com/news/zogenix-slumps-after-fda-refuses-epilepsy-drug-file/
Medicinal cannabis seizure prompts urgent question in ParliamentHealth secretary Matt Hancock responded to an urgent question tabled by Conservative MP Sir Mike Penning yesterday, following Share XMedicinal cannabis seizure prompts urgent question in Parliamenthttps://pharmaphorum.com/news/medicinal-cannabis-seizure-prompts-urgent-question-in-parliament/
UCB joins with UK charity to research new epilepsy drugsBelgium’s UCB has joined forces with the UK’s Epilepsy Society in a collaboration aimed at finding treatments for Share XUCB joins with UK charity to research new epilepsy drugshttps://pharmaphorum.com/news/ucb-joins-with-uk-charity-to-research-new-epilepsy-drugs/
NHS U-turns on Afinitor for TSC-related epilepsyNHS England has reversed a previous decision and will be funding Novartis’ Afinitor (everolimus) for TSC-related refractory epilepsy Share XNHS U-turns on Afinitor for TSC-related epilepsyhttps://pharmaphorum.com/news/nhs-u-turns-afinitor-tsc-related-epilepsy/
GW launches cannabis-based epilepsy drug in USGW Pharmaceuticals is bullish about the company’s prospects following the launch of its cannabis-based medicine for a rare Share XGW launches cannabis-based epilepsy drug in UShttps://pharmaphorum.com/news/gw-launches-cannabis-based-epilepsy-drug-in-us/
GW Pharma’s marijuana-based epilepsy drug approved in USThe FDA has approved UK-based GW Pharmaceuticals’ drug for a rare form of childhood epilepsy – the first Share XGW Pharma’s marijuana-based epilepsy drug approved in UShttps://pharmaphorum.com/news/gw-pharmas-marijuana-based-epilepsy-drug-approved-in-us/
FDA advisers back GW’s Epidiolex for rare epilepsyUK firm’s potential blockbuster on course for approval Share XFDA advisers back GW’s Epidiolex for rare epilepsyhttps://pharmaphorum.com/news/fda-advisers-back-gws-epidiolex-for-rare-epilepsy/
GW prepares US for cannabis-based epilepsy drugGW pushing for legal clearance in some states Share XGW prepares US for cannabis-based epilepsy drughttps://pharmaphorum.com/news/fda-reviewers-back-gw-pharmas-epilepsy-drug/